These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8623257)
61. Preventing anti-Gal response in xenograft recipients by an alpha-Gal toxin. Tanemura M; Yin D; DiSesa VJ; Galili U Transplant Proc; 2001; 33(1-2):699-700. PubMed ID: 11267025 [No Abstract] [Full Text] [Related]
62. Formation of heterophile antibodies by human tonsilar lymphocytes. II. In vitro stimulation with allogeneic cells. Mori T; Kano K; Merrick JM; Milgrom F Cell Immunol; 1981 Mar; 58(2):246-56. PubMed ID: 6971169 [No Abstract] [Full Text] [Related]
63. Use of anti-mu monoclonal antibody as a therapeutic approach to achieve depletion of xenoreactive natural antibodies. Soares M; Nisol F; Bach FH; Bazin H; Latinne D Transplant Proc; 1994 Jun; 26(3):1357-9. PubMed ID: 8029939 [No Abstract] [Full Text] [Related]
64. Enzyme-assisted synthesis of disaccharides to inhibit binding of human anti-alpha Gal antibody. Haga I; Satake M; Ohrui H; Ohkohchi N; Satomi S Transplant Proc; 1999 Nov; 31(7):2826-30. PubMed ID: 10578305 [No Abstract] [Full Text] [Related]
65. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Borrebaeck CK; Malmborg AC; Ohlin M Immunol Today; 1993 Oct; 14(10):477-9. PubMed ID: 8274187 [TBL] [Abstract][Full Text] [Related]
66. Inhibition of in vitro immunoglobulin synthesis by Brucella melitensis. Montag T; Tietz HJ; Liebenthal C; Lorf T; Mann W; Mehl M Tokai J Exp Clin Med; 1986; 11 Suppl():39-42. PubMed ID: 3502547 [No Abstract] [Full Text] [Related]
68. Natural anti-Gal antibodies constitute 0.2% of intravenous immunoglobulin and are equally retained on a synthetic disaccharide column or on an immobilized natural glycoprotein. Barreau N; Blancho G; Boulet C; Martineau A; Vusio P; Liaigre J; Bovin N; Bouhours D; Bouhours J Transplant Proc; 2000 Aug; 32(5):882-3. PubMed ID: 10936257 [No Abstract] [Full Text] [Related]
69. Diversity of natural anti-α-galactosyl antibodies in human serum. Lisowska E; Duk M Adv Exp Med Biol; 2011; 705():571-83. PubMed ID: 21618130 [No Abstract] [Full Text] [Related]
70. Removal of alphaGal antigens by ex vivo perfusion of pig kidneys with endo-beta-galactosidase C. Kobayashi T; Yokoyama I; Ogawa H; Muramatsu H; Kadomatsu K; Hayashi S; Liu D; Kato T; Tokoro T; Oikawa T; Takeuchi O; Morozumi K; Takagi H; Muramatsu T; Nakao A Transplant Proc; 2001; 33(1-2):763. PubMed ID: 11267058 [No Abstract] [Full Text] [Related]
71. In pursuit of xenoreactive antibodies: where has it gotten us? Parker W; Lesher AP Immunol Cell Biol; 2005 Aug; 83(4):413-7. PubMed ID: 16033537 [TBL] [Abstract][Full Text] [Related]
72. Adsorption of natural antibodies with acetone-treated tissue powder. Suga H; Hayasaka Y; Sato Y; Kimikawa M; Teraoka S; Agishi T; Ota K; Oguchi K Transplant Proc; 1992 Apr; 24(2):704. PubMed ID: 1533077 [No Abstract] [Full Text] [Related]
75. Human anti-B alloantibodies recognize xenoantigens on pig red blood cells and endothelial cells. Gautreau C; Woimant G; Grosse H; Cardoso J; Soubrane O; Houssin D Transplant Proc; 1996 Apr; 28(2):563. PubMed ID: 8623273 [No Abstract] [Full Text] [Related]
76. The humoral immune response in humans following ex vivo perfusion of porcine livers. Cotterell AH; Collins BH; Parker W; Harland RC; Platt JL Transplant Proc; 1996 Apr; 28(2):546. PubMed ID: 8623258 [No Abstract] [Full Text] [Related]
77. Clinical potential of xenotransplantation. Cooper DK; Koren E; Oriol R Transplant Proc; 1994 Jun; 26(3):1331-2. PubMed ID: 7518129 [No Abstract] [Full Text] [Related]
78. Natural anti-Gal antibodies prevent, rather than cause, autoimmunity in human Chagas' disease. Gazzinelli RT Res Immunol; 1991 Feb; 142(2):164-7. PubMed ID: 1907755 [No Abstract] [Full Text] [Related]
79. Human xenoreactive natural antibodies against Gal alpha (1-3) pig terminal residues are not produced by CD5+ B-lymphocytes. Pitre J; Möller E; Satake M Transplant Proc; 1996 Apr; 28(2):545. PubMed ID: 8623257 [No Abstract] [Full Text] [Related]